Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice

PURPOSE: To assess the effectiveness and safety of intravitreal aflibercept in clinically significant diabetic macular edema (DME) in daily clinical practice. METHODS: Prospective, open-label, single-center study. Anti-vascular endothelial growth factor naïve patients with clinically significant DME...

Descripción completa

Detalles Bibliográficos
Autores principales: Campos Polo, Rafael, Rubio Sánchez, Consuelo, García Guisado, Diego Manuel, Díaz Luque, María José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5764298/
https://www.ncbi.nlm.nih.gov/pubmed/29386883
http://dx.doi.org/10.2147/OPTH.S154421

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5764298/
https://www.ncbi.nlm.nih.gov/pubmed/29386883
http://dx.doi.org/10.2147/OPTH.S154421

Ejemplares similares